Primary packaging of pharmaceutical dosage forms should be designed, manufactured, processed and assembled in a way that does not alter the safety, identity, strength, quality or purity of the drug product beyond the established requirements. With complex forms of pharmaceuticals such as biologics entering the market, special requirements for handling, storage and packaging need to be met. Different materials such as glass and their characteristics regarding supplier issues, interactions with the drug product and end-user preferences will be discussed as well as the latest regulatory updates such as the Annex 1 of the European GMP Guideline and USP 800. Topics to be explored will further include some of the latest developments in packaging materials & components and the role of Container Closure Integrity (CCI) in product-package development, assembly and processing. The week’s program of the 2019 PDA Europe Parenteral Packaging conference is intended to initiate and support discussion and professional exchange through a diversity of scientific presentations, workshops, training courses, joint dinners and networking events.
We look forward to you joining us in amazing Venice!
Roger Asselta, Genesis Packaging Technologies
Roman Mathaes, Lonza
If this page is in your subscriptions, then it will be removed. You will not see this page. If you want to unblock a user, go to the settings, the list of blocked users and click unblock
Select chat category